Apolipoprotein C-I genotype and serum levels of triglycerides, C-reactive protein and coronary heart disease

Apolipoprotein C-I (apoCI) is implicated in lipid metabolism and inflammatory response, both important risk factors for human heart disease. However, most findings come from in vitro or animal studies, whereas data on human apoCI are sparse. To elucidate the role of apoCI in human disease, we analyzed a functional polymorphism in the promoter region of the apoCI gene in relation to blood lipids, C-reactive protein (CRP), coronary artery disease (CAD), and myocardial infarction (MI). Rs11568822 is a 4-base pair insertion/deletion (Ins/Del) polymorphism, and the Ins allele leads to a higher transcription in vitro compared with the Del allele. This polymorphism was analyzed in the Intergene study, a case-control study for CAD (N=1236), and the Stockholm Heart Epidemiology Program, a case-control study for MI (N=2774). Subjects homozygous for the Ins genotype had significantly higher serum levels of triglycerides (P=.01 and P=.006) and lower serum levels of CRP (P=.02 and P <.0001) compared with all other subjects in both studies. Similar results were obtained when analyzing only the controls of both studies (P=.002 and P=.0002, triglycerides; P=.002 and P <.0001, CRP). However, apoCI was not associated with CAD or MI. In conclusion, our data show that apoCI genotype is associated with serum levels of triglycerides and CRP, confirming the role of apoCI in lipid metabolism and suggesting that it also influences inflammation. (C) 2010 Elsevier Inc. All rights reserved.